Yahoo Finance • 5 months ago
Ultragenyx Pharmaceutical Inc. Treatment with DTX401 resulted in a statistically significant reduction in daily cornstarch intake at Week 48 (p<0.0001) with maintenance of glucose control Company will host investor call today at 5:00 p.m... Full story
Yahoo Finance • 5 months ago
Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells The estate of Henrietta Lacks can proceed with a lawsuit against Ultragenyx Pharmaceutical (NASDAQ:RARE) over the use of cells taken from Lacks’ body in the 1950s,... Full story
Yahoo Finance • 6 months ago
Ultragenyx Pharmaceutical Inc. NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that all patients have been enrolled across the Phase 3 Orbit and Cosmic studies evaluating se... Full story
Yahoo Finance • 8 months ago
Ultragenyx Pharmaceutical Inc. NOVATO, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and u... Full story
Yahoo Finance • 9 months ago
Ultragenyx Pharmaceutical (NASDAQ:RARE) Full Year 2023 Results Key Financial Results Revenue: US$434.2m (up 20% from FY 2022). Net loss: US$606.6m (loss narrowed by 14% from FY 2022). US$8.25 loss per share (improved from US$10.12 loss i... Full story
Yahoo Finance • 9 months ago
In this piece, we will take a look at the 15 best strong buy stocks to invest in. If you want to skip our overview of analyst ratings and the finance industry, then you can take a look at the 5 Best Strong Buy Stocks To Invest In. The fin... Full story
Yahoo Finance • 10 months ago
Ultragenyx Pharmaceutical Inc. NOVATO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the National Institute for Health and Care Excellence (NICE) has issued a final draft guid... Full story
Yahoo Finance • 10 months ago
Ultragenyx Pharmaceutical Inc. Data from at least 20 patients enrolled in dose expansion cohorts anticipated in the first half of 2024 NOVATO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a bio... Full story
Yahoo Finance • 10 months ago
Ultragenyx Pharmaceutical Inc. NOVATO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious ra... Full story
Yahoo Finance • 10 months ago
In this piece, we will take a look at the 13 most promising stocks to buy according to hedge funds. If you want to skip our overview of the latest stock market news, then you can take a look at the 5 Most Promising Future Stocks To Buy. I... Full story
Yahoo Finance • 12 months ago
6th Annual Evercore ISI HealthCONxon November 28 in Miami Piper Sandler 35th Annual Healthcare Conference on November 29 in New York City NOVATO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE),... Full story
Yahoo Finance • 12 months ago
NOVATO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic disea... Full story
Yahoo Finance • last year
ROMA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), azienda biofarmaceutica focalizzata sullo sviluppo e la commercializzazione di nuove terapie per malattie genetiche rare e ultra rare, ha annunciato o... Full story
Yahoo Finance • last year
In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Click to skip past our discussion of the biotech space and straight to the 5 Best Small-Cap Biotech Stocks with Massiv... Full story
Yahoo Finance • last year
Ultragenyx Pharmaceutical Inc. Third quarter 2023 total revenue of $98.1 million, Crysvita® revenue of $74.9 million and Dojolvi® revenue of $16.6 million Reaffirmed 2023 expected total revenue guidance between $425 million to $450 milli... Full story
Yahoo Finance • last year
NOVATO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseas... Full story
Yahoo Finance • last year
LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments a... Full story
Yahoo Finance • last year
NOVATO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today annou... Full story
Yahoo Finance • last year
NOVATO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today annou... Full story
Yahoo Finance • last year
NOVATO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today annou... Full story